CAS 1841-19-6 MFCD00055137-Fluspirilene 氟斯必灵 TAO{mole}

Fluspirilene 氟斯必灵

CAS 1841-19-6 MFCD00055137

化学结构图

SMILES: O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2

化学属性

Mol. Formula	C29H31F2N3O
Mol. Weight	475.57

别名和识别编码

Chemical Name	Fluspirilene
CAS Number	1841-19-6
Synonym	1-Phenyl-4-oxo-8-(4,4-bis(4-fluorophenyl)butyl)-1,3,8-triazaspiro(4,5)decane 8-(4,4-Bis(p-fluorophenyl)butyl)-1-phenyl-1,3,8-triazaspiro(4,5)decan-4-one 8-[4,4-Bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one 8-[4,4-bis(p-Fluorophenyl)butyl]-1-phenyl-1,3,8-triazino[4.5]decan-4-one R 6218 Fluspirilen Fluspirilene Fluspiriline IMAP Imap McN-JR 6218 McN-JR-6218 R 6218 Redeptin
MDL Number	MFCD00055137
PubChem Substance ID	3396
EC Number	217-418-6
Chemical Name Translation	氟斯必灵
Wiswesser Line Notation	T6N DXTJ A3YR DF&R DF& D-& CT5MVXN EHJ DR
Beilstein Registry Number	0633853
LabNetwork Molecule ID	LN01343719
InChI	InChI=1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)

信息真实价格透明资金保障专业采购外包团队在线服务

品牌质保精细包装现货库存一流品牌服务

分类

{SNA} Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Calcium Channel Modulators, Dopaminargics - Antagonists, Dopaminergics, F, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, Inhibitors and Activators, Ion Channels, Johnson & Johnson, Membrane Protein Biology Tools, Neuroscience, Neurotransmission, Neurotransmitters, Voltage-gated Ion Channels, 生化试剂, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学, 蛋白质及衍生物
Heterocycles
{SNA} Antagonists, Approved Therapeutics/Drug Candidates,

产品应用

Fluspirilene is a diphenylbutylpiperidine antipsychotic drug, used for the treatment of schizophrenia.

安全信息

RTECSXX8750000

WGK Germany3

Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

Storage condition room temp

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 183 ug/kg
TOXIC EFFECTS :
   Skin and Appendages - corrosive (after topical exposure)
REFERENCE :
   BMJOAE British Medical Journal.  (British Medical Assoc., BMA House,
   Tavistock Sq., London WC1H 9JR, UK)  V.1-    1857- Volume(issue)/page/year:
   1,523,1979

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : >146 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 20,1689,1970

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Mammal - dog
DOSE/DURATION           : >37 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 20,1689,1970

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - guinea pig
DOSE/DURATION           : >80 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   ARZNAD Arzneimittel-Forschung. Drug Research.  (Editio Cantor Verlag,
   Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.)  V.1-    1951-
   Volume(issue)/page/year: 20,1689,1970

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intr